About Light Chain Amyloidosis
Light Chain Amyloidosis results from clonal plasma cell proliferation producing excessive amounts of misfolded immunoglobulin light chains (kappa or lambda) that cannot be properly degraded. These misfolded proteins aggregate to form amyloid fibrils that deposit in various tissues, causing progressive organ dysfunction.
The heart is affected in approximately 50-70% of patients, leading to restrictive cardiomyopathy with diastolic dysfunction, arrhythmias, and sudden cardiac death. Renal involvement occurs in 40-50% of patients, presenting as nephrotic syndrome with heavy proteinuria. Peripheral neuropathy develops in approximately 10-15% of patients, ranging from small fiber neuropathy to autonomic dysfunction. Other affected organs include liver, eyes, gastrointestinal tract, and soft tissues.
The underlying plasma cell clone is usually modest in size and may not meet criteria for multiple myeloma. Early diagnosis is critical, as untreated disease rapidly progresses to multi-organ failure. Median survival without treatment is approximately 2-4 years when cardiac involvement is present.
Common Symptoms of Light Chain Amyloidosis
Recognizing the signs of Light Chain Amyloidosis early can lead to faster diagnosis and better outcomes. Symptoms may vary in severity from person to person. If you or a loved one are experiencing any of the following, consider speaking with a specialist.
- Fatigue and weakness
- Shortness of breath and heart failure symptoms
- Swelling in ankles, feet, legs, and abdomen (edema)
- Numbness, tingling, or pain in hands and feet (peripheral neuropathy)
- Proteinuria (protein in urine) and kidney dysfunction
- Unexplained weight loss
Who Light Chain Amyloidosis Affects
Light Chain Amyloidosis typically affects older adults, with median age of diagnosis around 63 years, though younger patients can be affected. It affects males more frequently than females. The disease occurs across all racial and ethnic groups. It predominantly affects individuals of European ancestry, though increasing recognition in other populations suggests possible underdiagnosis.
Find Your Next Step
FDA-Approved Treatments for Light Chain Amyloidosis
There is currently 1 FDA-approved medication for Light Chain Amyloidosis. These therapies represent the current standard of care and may be used alongside or compared against investigational treatments in active clinical trials.
Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.
Help Paying for Light Chain Amyloidosis Treatment
Charity funds and drugmaker programs for Light Chain Amyloidosis, checked at the source.
- From a charity · HealthWell FoundationAmyloidosis fundOpen
Pays for: Copays, premiums or other treatment costs.
- From a charity · NORD RareCareAmyloidosis Medical Assistance fundOpen
Pays for: Medical and medication costs.
The foundation says: “Accepting Applications” - From a charity · NORD RareCareAmyloidosis Premium Copay Assistance fundOpen
Pays for: Insurance premiums and copays.
The foundation says: “Accepting Applications” - From a charity · TotalAssist (formerly PAN Foundation)Amyloidosis fundOpen
Pays for: Out-of-pocket costs for approved medications, up to $5,500 per year. Requires Medicare, Medicaid or TRICARE.
- From a charity · The Assistance FundAmyloidosis fundWaitlist
Pays for: Copays, coinsurance, deductibles and other health-related expenses.
The foundation says: “WAITLIST — Accepting Waitlist Patients. TAF is currently accepting requests to join the enrollment waitlist for this program. Waitlists a…”
Side Effect Explorer
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Genetic Testing
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted Light Chain Amyloidosis Resources
Reputable organizations and medical references for learning more about Light Chain Amyloidosis, including disease registries, foundation resources, and clinical guidelines.